| Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins | Sarah de Crescenzo | 06/04/20 | Boston |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone | Frank Vinluan | 09/06/19 | National |
| It’s Tough to Find Drugs to Bind to RNA: Arrakis Nabs $75M to Help | Frank Vinluan | 04/18/19 | Boston |
| Ribometrix Takes Aim at “Undruggable” RNA with $30M Series A Funding | Corie Lok | 11/13/18 | Raleigh Durham |
| In New York, Gotham Starts Up With $54M for RNA-Modifying Drugs | Corie Lok | 10/10/18 | New York |
| Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout | Alex Lash | 05/18/18 | National |
| Accent Therapeutics Debuts With $40M To Target RNA Modification | Corie Lok | 05/18/18 | Boston |
